PFIZER, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.88 USD | +0.66% |
|
+0.84% | +0.31% |
| 05-24 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
| 05-23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
Presenter SpeechMatthew Harrison (Analysts)Thank you for joining us for the next session. I'm ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.88
USD
Average target price
31.94
USD
Spread / Average Target
+10.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.31% | 164B | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Transcript : Pfizer Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-14-2021 10
